Health Condition 1: N428- Other specified disorders of prostate
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Pfizer Products India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed and/or treated with mCSPC or mCRPC 01 January 2023 onwards, inclusive. mCSPC is defined as the current and/or historical presence of metastases on any imaging modality sensitive to hormone therapy. mCRPC is defined as the current and/or historical presence of metastases on any imaging modality with evidence of disease progression (a rising PSA or radiographic progression (as defined by the investigator) despite ongoing castration therapy [ADT or prior surgical orchiectomy]).1,9 Aged at least 18 years upon diagnosis of mCSPC or mCRPC.
Exclusion criteria
Exclusion criteria: Previously enrolled in an interventional trial related to metastatic prostate cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe demographic and clinical characteristics at first diagnosis of metastatic adenocarcinoma of prostate (mCSPC and mCRPC). Document treatment patterns from original prostate cancer diagnosis in both mCSPC and mCRPC. Assess clinical outcomes among patients diagnosed with mCSPC and mCRPC, including PSA response and real-world progression-free survival (PFS) in DDR mutation/wild type, ORR, and OS. Report mCRPC-specific HCRU. Document time on treatment for each line of treatment for mCSPC and mCRPC. Document time to next treatment from initiation of a systemic therapy line to the commencement of the subsequent systemic therapy line for mCSPC and mCRPC. Document time to subsequent chemotherapy from initiation of first-line systemic treatment for mCSPC and mCSPC.Timepoint: 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Antara Chaudhri
Pfizer Products India Private Limited
Outcome results
None listed